000109350 001__ 109350
000109350 005__ 20230519145423.0
000109350 0247_ $$2doi$$a10.3389/fcimb.2021.709749
000109350 0248_ $$2sideral$$a125443
000109350 037__ $$aART-2021-125443
000109350 041__ $$adeu
000109350 100__ $$0(orcid)0000-0002-0531-0943$$aGonzález, Andrés$$uUniversidad de Zaragoza
000109350 245__ $$aFighting the antibiotic crisis: flavonoids as promising antibacterial drugs against Helicobacter pylori infection
000109350 260__ $$c2021
000109350 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109350 5203_ $$aOver half of the world’s population is estimated to be infected with Helicobacter pylori. Chronic infection with this microbial class I carcinogen is considered the most important risk factor for developing gastric cancer. The increasing antimicrobial resistance to first-line antibiotics mainly causes the failure of current eradication therapies, inducing refractory infections. The alarming increase in multidrug resistance in H. pylori isolates worldwide is already beginning to limit the efficacy of existing treatments. Consequently, the World Health Organization (WHO) has included H. pylori in its list of “priority pathogens” for which new antibiotics are urgently needed. Novel strategies must be followed to fight this antibiotic crisis, including properly exploiting the proven therapeutic potential of medicinal plants and plant-derived phytochemicals. In this mini-review, we overview the impressive properties of naturally occurring flavonoids as effective antimicrobial agents against H. pylori, which support the use of these plant-derived bioactive compounds as promising drug candidates for inclusion in novel and personalized combinatory therapies against H. pylori infection.
000109350 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B25-17R
000109350 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109350 590__ $$a6.073$$b2021
000109350 592__ $$a1.389$$b2021
000109350 594__ $$a5.9$$b2021
000109350 591__ $$aMICROBIOLOGY$$b33 / 138 = 0.239$$c2021$$dQ1$$eT1
000109350 593__ $$aImmunology$$c2021$$dQ1
000109350 591__ $$aIMMUNOLOGY$$b53 / 163 = 0.325$$c2021$$dQ2$$eT1
000109350 593__ $$aMicrobiology (medical)$$c2021$$dQ1
000109350 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000109350 593__ $$aInfectious Diseases$$c2021$$dQ1
000109350 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109350 700__ $$aCasado, Javier
000109350 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000109350 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000109350 773__ $$g11 (2021), 709749 [9 pp.]$$tFrontiers in Cellular and Infection Microbiology$$x2235-2988
000109350 8564_ $$s544091$$uhttps://zaguan.unizar.es/record/109350/files/texto_completo.pdf$$yVersión publicada
000109350 8564_ $$s2298913$$uhttps://zaguan.unizar.es/record/109350/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109350 909CO $$ooai:zaguan.unizar.es:109350$$particulos$$pdriver
000109350 951__ $$a2023-05-18-14:09:38
000109350 980__ $$aARTICLE